COVID-19 antibody based treatment soon in India |
India`s Biocon Biologics announced that the US-based Adagio Therapeutics has granted an exclusive license to Biocon to manufacture and commercialise a COVID-19 antibody treatment based on ADG20 for India and select emerging markets. ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19. Initial data indicate that ADG20 could provide both rapid and durable protection against COVID-19 for up to one year. This could help significantly reduce COVID-19 related hospitalisations and deaths. ADG20 has the potential to address resistant variants, including the Delta variant, and can be administered easily as a single, intramuscular injection in the outpatient setting. Biocon Biologics Executive Chairperson Kiran Mazumdar-Shaw said the partnership with Adagio will bring superior biologic therapies to millions of patients in low and middle-income countries. She said vaccines alone will not protect and make the world safer. Adagio has published preliminary data from its ongoing Phase 1 trial in healthy volunteers, which support ADG20`s safety and pharmacokinetic profile and SARS-CoV-2 neutralising activity. Adagio is currently conducting two global Phase 2/3 clinical trials, which will support an Emergency Use Authorization (EUA) submission in the U.S.
|
|
|
|